JAMES SATTESON: Open Payments
NPI 1669146882 · SHAMOKIN DAM, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,077 in 56 payments from 18 companies in 2025. Trend: 2023 $834 · 2024 $1,146 · 2025 $1,077
Food & beverage: $1,032Education: $45
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 10 | $192 |
| Novo Nordisk Inc | 8 | $160 |
| ABBVIE INC. | 8 | $152 |
| Lilly USA, LLC | 5 | $122 |
| GlaxoSmithKline, LLC. | 6 | $100 |
| Dexcom, Inc. | 3 | $69 |
| Paratek Pharmaceuticals, Inc. | 3 | $54 |
| Phathom Pharmaceuticals, Inc. | 2 | $31 |
| Amgen Inc. | 2 | $29 |
| Otsuka America Pharmaceutical, Inc. | 1 | $28 |
Products named: AIRSUPRA, Ozempic, QULIPTA, Dexcom G6 Transmitter, MOUNJARO, NUZYRA, BEXSERO, VRAYLAR.
Industry payments across PA — which companies pay providers there.
